Medical University of South Carolina
Charleston, South Carolina, 29425, United States
NCT Number: NCT03937921
The overall goal of this study is to investigate the signal intensity and relaxation rate characteristics of gadoterate meglumine (Dotarem, Guerbet, USA) enhanced myocardium during rest and stress perfusion cardiovascular magnetic resonance (CMR) compared to gadobutrol (Gadavist) to prove that Dotarem provides constantly high myocardial relaxation necessary for accurate quantitative perfusion evaluation.
The purpose of this study is to compare two types of contrast that patients receive during cardiac MRI scans to visualize the blood flow in the cardiac muscle. Both contrasts are used in standard of care procedures, and the one administered for each patient will be randomly selected. The length of the MRI study all procedures are the same as the clinically indicated scan.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Charleston, South Carolina, 29425, United States
The overall goal of this study is to investigate the signal intensity and relaxation rate characteristics of gadoterate meglumine (Dotarem, Guerbet, USA) enhanced myocardium during rest and stress perfusion cardiovascular magnetic resonance (CMR) compared to gadobutrol (Gadavist) to prove that Dotarem provides constantly high myocardial relaxation necessary for accurate quantitative perfusion evaluation. Within this overall goal, the following specific aims will be pursued:
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Aim 1
Inclusion criteria
To be eligible for the study: (All answers must be "YES" for subject to be eligible.)
Exclusion criteria
The presence of the following excludes subjects from the study: (All answers must be "NO" for subject to be eligible.)
Aim 2
Inclusion criteria
To be eligible for the study: (All answers must be "YES" for subject to be eligible.)
Exclusion criteria
The presence of the following excludes subjects from the study: (All answers must be "NO" for subject to be eligible.)
Group 2 (n=30) will receive the clinically approved gadobutrol (Gadavist, 0.1mmol/kg) as contrast agent. The contrast agents will be administered at a flow rate of 5.0 ml/s for both groups. In this study aim, all imaging protocols will comply with standard of care and only the perfusion data will be post-processed and analyzed.
Time frame: 1 year
Characteristics of signal intensity changes and absolute myocardial blood flow using the MASS Research Software; signal intensity-time curves from the perfusion data
Time frame: 1 year
The uniformity of T1 and R1 (inverse T1) evaluated using the MASS Research Software; equilibrium T1 maps generated by pre-contrast T1 and repeat inversion recovery images during the perfusion of the coronary arteries
Medical University of South Carolina
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03180060
Cardiovascular Diseases, Coronary Angiography
Mexico City, Mexico
View Trial DetailsNCT01490294
Magnetic Resonance Imaging, Myocardial Perfusion Imaging
Pölten, Austria
View Trial DetailsNCT04465526
Cardiovascular Diseases, Coronary Disease
Warsaw, Poland
View Trial DetailsNCT03173716
Myocardial Perfusion Imaging
Rochester, Minnesota, United States
View Trial Details